Rampart Bioscience, a La Jolla, CA-based biotechnology company developing next-generation biologics, raised $85M in Series A funding.
The round was led by Forbion with participation from seed investor OrbiMed and additional new investors RA Capital Management and HealthCap.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Louis Breton, and Jeffrey Bartlett, Ph.D., Co-founder and Chief Innovation and Technical Officer, Rampart Bioscience leverages the DNA-based medicines HALO platform to produce highly potent, durable, and redosable therapies. The company’s lead program is for the treatment of hypophosphatasia (HPP), a rare, often fatal genetic disease that prevents bone mineralization.
Rampart has additional programs in development.
FinSMEs
24/10/2023